PR98707

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

PERUGIA, Italy, Nov. 9, 2022, /PRNewswire=KYODO JBN/--

INT-787 is a selective next generation FXR agonist invented by TES Pharma and

licensed to Intercept Pharmaceuticals

INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal

models

TES Pharma is dedicated to the identification of novel therapeutic targets and

the discovery and development of new molecules to efficiently address the needs

of patients with serious oncological and metabolic conditions

TES Pharma Srl, an Italian biotechnology company focused on the discovery and

development of novel drug products for the treatment of diseases of high unmet

medical need, congratulates Intercept Pharmaceuticals, Inc., on the

presentation  of data from their ongoing first-in-human study of INT-787 and

the initiation of the phase 2a FRESH (FxR Effect on Severe Alcohol-Associated

Hepatitis) study, a trial evaluating the safety, tolerability, efficacy and

pharmacokinetics of INT-787 in subjects with sAH.  INT-787 is a selective next

generation Farnesoid X Receptor (FXR) agonist invented by TES Pharma, and

licensed to Intercept Pharmaceuticals within the framework of a licence and

collaboration agreement.  Details of the clinical studies can be found at

www.interceptpharma.com.

Professor Roberto Pellicciari, the founder and CEO of TES Pharma, is also the

inventor of obeticholic acid (OCA), a prototypic bile acid derived FXR agonist

which is approved for the treatment of primary biliary cholangitis (PBC) and

commercialised by Intercept Pharmaceuticals in the United States.  PBC is a

progressive autoimmune disease that damages the bile ducts in the liver and is

a leading cause of chronic liver disease leading to liver transplantation.

INT-787 has distinct pharmacological properties that differ from those of OCA

and has shown strong anti-fibrotic and anti-inflammatory effects in animal

models.  Data from a murine NASH model comparing OCA and INT-787 were also

presented at the American Association for the Study of Liver Diseases (AASLD)

meeting.

"We are proud of the work we do at TES Pharma, and very pleased about the

ongoing first-in-human study of INT-787 and the initiation of the Phase 2a

FRESH study in patients with severe alcohol-associated hepatitis, important

milestones that encourage us to continue our mission to find new treatments to

improve people's lives, especially for patients suffering from serious

diseases", said Prof. Pellicciari.

TES Pharma is a research-based biotech company, located in Perugia (Italy),

dedicated to the identification of novel therapeutic targets and the discovery

and development of new molecules to efficiently address the needs of patients

with serious oncological and metabolic conditions. More information about TES

Pharma can be found at www.tespharma.com.

TES Pharma was founded in 2011 by Prof. Pellicciari together with Drs. Antimo

Gioiello, Antonio Macchiarulo, and Janet Robertson.  Prior to founding TES

Pharma, Prof. Pellicciari led the Medicinal Chemistry Research Group at the

Department of Chemistry and Drug Technologies of the University of Perugia.

CONTACT:

Prof. Roberto Pellicciari

rpellicciari@tespharma.com ,

Phone: +39 075 6978111

E: info@tespharma.com

F: +39 075 6978882

GSM: +39 366 9057122

Logo - https://mma.prnewswire.com/media/1941775/TES_Pharma_Logo.jpg

SOURCE: TES Pharma